Literature DB >> 22315714

Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Tony Wyss-Coray1, Joseph Rogers.   

Abstract

Biochemical and neuropathological studies of brains from individuals with Alzheimer disease (AD) provide clear evidence for an activation of inflammatory pathways, and long-term use of anti-inflammatory drugs is linked with reduced risk to develop the disease. As cause and effect relationships between inflammation and AD are being worked out, there is a realization that some components of this complex molecular and cellular machinery are most likely promoting pathological processes leading to AD, whereas other components serve to do the opposite. The challenge will be to find ways of fine tuning inflammation to delay, prevent, or treat AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315714      PMCID: PMC3253025          DOI: 10.1101/cshperspect.a006346

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  244 in total

1.  Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo.

Authors:  Nattinee Jantaratnotai; Jae K Ryu; Seung U Kim; James G McLarnon
Journal:  Neuroreport       Date:  2003-08-06       Impact factor: 1.837

2.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.

Authors:  Seung-Yong Seong; Polly Matzinger
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

Review 3.  Astroglia in dementia and Alzheimer's disease.

Authors:  J J Rodríguez; M Olabarria; A Chvatal; A Verkhratsky
Journal:  Cell Death Differ       Date:  2008-12-05       Impact factor: 15.828

4.  Development of microglia in the chick embryo spinal cord: implications in the regulation of motoneuronal survival and death.

Authors:  Jordi Calderó; Núria Brunet; Dolors Ciutat; Marta Hereu; Josep E Esquerda
Journal:  J Neurosci Res       Date:  2009-08-15       Impact factor: 4.164

5.  Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human beta-amyloid.

Authors:  Jeffrey M Craft; D Martin Watterson; Alexander Marks; Linda J Van Eldik
Journal:  Glia       Date:  2005-08-15       Impact factor: 7.452

Review 6.  The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection.

Authors:  A L D'Ambrosio; D J Pinsky; E S Connolly
Journal:  Mol Med       Date:  2001-06       Impact factor: 6.354

7.  Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease.

Authors:  Silke Walter; Maryse Letiembre; Yang Liu; Holger Heine; Botond Penke; Wenlin Hao; Barbara Bode; Nicole Manietta; Jessica Walter; Walter Schulz-Schuffer; Klaus Fassbender
Journal:  Cell Physiol Biochem       Date:  2007

8.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

9.  Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice.

Authors:  J Sanchez-Ramos; S Song; V Sava; B Catlow; X Lin; T Mori; C Cao; G W Arendash
Journal:  Neuroscience       Date:  2009-06-14       Impact factor: 3.590

10.  Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin.

Authors:  Milan Fiala; Philip T Liu; Araceli Espinosa-Jeffrey; Mark J Rosenthal; George Bernard; John M Ringman; James Sayre; Laura Zhang; Justin Zaghi; Sheila Dejbakhsh; Ben Chiang; James Hui; Michelle Mahanian; Anita Baghaee; Pamela Hong; John Cashman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-24       Impact factor: 11.205

View more
  358 in total

Review 1.  Deciphering Alzheimer disease.

Authors:  Dennis Selkoe; Eckhard Mandelkow; David Holtzman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Getting to the Heart of Alzheimer Disease.

Authors:  Joshua M Tublin; Jeremy M Adelstein; Federica Del Monte; Colin K Combs; Loren E Wold
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

3.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

Review 4.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

Review 5.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

Review 6.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

7.  The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.

Authors:  Panos Roussos; Pavel Katsel; Peter Fam; Weilun Tan; Dushyant P Purohit; Vahram Haroutunian
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

8.  siRNA-mediated silencing of phosphodiesterase 4B expression affects the production of cytokines in endotoxin-stimulated primary cultured microglia.

Authors:  Hao Cheng; Zhifang Wu; Xiaoyun He; Qingzhen Liu; Hongbin Jia; Yan Di; Qing Ji
Journal:  Exp Ther Med       Date:  2016-08-04       Impact factor: 2.447

9.  Taxifolin prevents β-amyloid-induced impairments of synaptic formation and deficits of memory via the inhibition of cytosolic phospholipase A2/prostaglandin E2 content.

Authors:  Yuanyuan Wang; Qinwen Wang; Xiaoming Bao; Yanfei Ding; Jieyi Shentu; Wei Cui; Xiaowei Chen; Xiaofei Wei; Shujun Xu
Journal:  Metab Brain Dis       Date:  2018-03-14       Impact factor: 3.584

10.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Authors:  Cliona Stack; Shari Jainuddin; Ceyhan Elipenahli; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Mariona Jové; Manuel Portero-Otin; Nathalie Launay; Aurora Pujol; Navneet Ammal Kaidery; Bobby Thomas; Davide Tampellini; M Flint Beal; Magali Dumont
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.